Gastrointestinal Cancer News

The FDA approved nivolumab for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after receiving fluoropyrimidine- and platinum-based chemotherapy.

Fam-trastuzumab deruxtecan-nxki significantly improved outcomes compared with chemotherapy among patients with HER2-positive gastric cancer, according to study results presented during the ASCO20 Virtual Scientific Program.

The National Comprehensive Cancer Network and NCCN Foundation announced five recipients of the 10th annual NCCN Foundation Young Investigator Awards.

A single 300 mg priming dose of tremelimumab in combination with durvalumab appeared safe and active among patients with advanced hepatocellular carcinoma, according to study results presented during the ASCO20 Virtual Scientific Program.

Donafenib conferred a modest but statistically significant OS improvement as first-line therapy for advanced hepatocellular carcinoma, according to study results presented during the ASCO20 Virtual Scientific Program.

The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Trastuzumab deruxtecan demonstrated durable benefit among patients with HER2-expressing metastatic colorectal cancer, according to findings of the phase 2 DESTINY-CRC01 study presented during the ASCO20 Virtual Scientific Program.

First-line pembrolizumab extended PFS vs. chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to findings to be presented during the ASCO20 Virtual Scientific Program.

The FDA granted priority review to two cancer treatment regimens.